AIM
UTMD icon

Acrospire Investment Management’s Utah Medical Products UTMD Stock Holding History

Acrospire Investment Management’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,919
Closed -$139K – 1369
2017
Q2 		$139K Buy
1,919
+1,482
+339% +$97.5K 0.13% 99
2017
Q1 		$27K Sell
437
-1,068
-71% -$67.2K 0.02% 1432
2016
Q4 		$109K Sell
1,505
-1,093
-42% -$71.1K 0.04% 870
2016
Q3 		$155K Buy
2,598
+621
+31% +$39.5K 0.1% 260
2016
Q2 		$125K Buy
1,977
+401
+25% +$25.9K 0.09% 286
2016
Q1 		$99K Buy
+1,576
New +$92.9K 0.07% 326

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Acrospire Investment Management's UTMD Position: Q3 2017 in Review

Acrospire Investment Management sold out of Utah Medical Products (UTMD) in Q3 2017, closing a stake of 1,919 shares — an estimated $139K sold.

Acrospire Investment Management first reported a position in UTMD in Q1 2016 and held it in 6 quarters. The position peaked at $155K in Q3 2016. 74 funds tracked by Wall St. Rank hold UTMD as of Q3 2017.

  • Acrospire Investment Management reported no remaining Utah Medical Products position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,919 Utah Medical Products shares in Q3 2017, an estimated $139K.
  • Acrospire Investment Management first reported a position in Utah Medical Products in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Utah Medical Products position peaked at $155K in Q3 2016.
  • 74 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.